Global Antiulcerant Drugs Market - 2021-2028
The global antiulcerant drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Antiulcerant drugs are a class of drugs or antibacterial agents that are used to treat ulcers especially in the stomach, upper part of the small intestine and other parts of body. Antiulcerant drugs are also gaining popularity in the treatment of diarrhea or address an irritable gastrointestinal tract in patients.
The global antiulcerant drugs market market growth is driven by the as increasing unhealthy habits, rising population in the developing countries, swamped lifestyle and high prevalence of diabetes leading to foot ulcers.
There has been rising awareness about ulcer diseases, which has been imparting an increasing momentum to the evolution of the antiulcerant drugs market. The pipeline of promising antiulcerant drugs has been rising over the past few years in various parts of the world. In recent years, the pharmacology of antiulcerant drugs has received considerable attention by pharmaceutical companies, which has helped them develop drugs with better clinical results. The rising incidence of peptide ulcers, especially in people with sedentary lifestyle, is also catalyzing the growth of the global antiulcerant drugs market. The rising acceptance of antacids in anti-ulcer agents among the patient population for symptomatic relief is also a significant boosting the market..
There is prevalence of infection with H. pylori in communities with the lack of access to clean water and proper sewage systems. This if untreated may lead to peptic ulcer disease, and antiulcerant drugs play crucial role in there treatment. The growing mortality of thrombotic events, especially in tuberculosis patients, is also likely to accentuate prospects of the antiulcerant drugs market in the coming few years. The rising risk of adverse cardiovascular events related to patients treated with aspirin has fueled the uptake of antiulcerant drugs. In recent years, several pharmaceuticals have been actively working to adopt advanced technologies for manufacturing anatacids. Moreover, they are spending sizeable sums on accelerating their drug pipelines. This will open new, exciting avenues in the global market.
However, various side effects of the drug such as vomiting, nausea, menstrual disorders and stringent government regulations and policies related to drug patents may restrict the growth of the market. Since prediction of occurrence of life-threatening effects is difficult, it is important to correctly consider indications and administer antiulcerant drugs only to patients who truly need it. In addition, patients should be instructed to report unexplained skin eruptions, fever, or general malaise appearing after starting a antiulcerant drugs administration to their attending physician without delay. Doctors also should check for possible adverse effects within the first few weeks after starting an administration by scheduling follow-up consultation sessions.
The current utility-owned antiulcerant drugs market is affected mainly by the COVID-19 (Corona Virus Disease) pandemic. There has been delay in most ofthe projects that are in China, the US, Germany and South Korea, as well as companies in these regions are also facing temporaryoperative issues due to absence of site access and constrains in the supply chain. Due to the outburst of COVID-19 in china, Japan and India have shortage of these drugs. Thesse factors are restraning the growth of the market in the forecast period.
H2 receptor antagonist, in full histamine receptor H2 antagonist, any agent that blocks histamine-induced secretion of gastric acid in the stomach. These drugs, which include cimetidine (Tagamet) and ranitidine (Zantac), are used for short-term treatment of gastroesophageal reflux and, in combination with antibiotics, for peptic ulcer.
According to International Foundation for Gastrointestinal Disorders, Inc., the prevalence of gastroesophageal reflux disease (GERD) was 18.1% to 27.8% in North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America in 2019. GERD is a chronic and highly prevalent disorder that can potentially lead to serious medical complications, and the medical expense involved in the diagnosis, treatment, and management of the disease is significant.
Rising awareness about gastroesophageal reflux disease and acid-peptic disease, availability of treatment options, and management of these diseases, have increased the demand for the treatment of H2-receptor antagonists in developing countries. Governments and other non-profit organizations spread awareness and educate people about gastric acid management through campaigns and educational and clinical workshops. These factors are driving the growth of the market in the forecast period.
Sores that develop on the lining of stomach, esophagus, and intestines are called peptic ulcers. Symptoms of peptic ulcers include vomiting, burning stomach pain, bloating, and food intolerance. Some of the causes of peptic ulcers are stomach infections caused by H. pylori, alcoholism, stomach cancers, usage of anti-inflammatory drugs such as aspirin. Peptic ulcers, if untreated, can cause severe complications such as internal bleeding and perforation in the stomach lining. Lifestyle related factors such as aerated drinks, alcoholism, consumption of fatty food, and stress can cause peptic ulcers. Peptic ulcers can cause severe morbidity in the geriatric population. Hence, increase in this population is a key factor projected to drive the market during the forecast period. Furthermore, increase in patient pool and rise in consumption of drugs such as aspirin, ibuprofen, and other inflammatory drugs are the other factors which drives the market in the forecast period.
North America region is dominating the global antiulcerant drugs accounted for the largest market share. Rise in awareness about peptic ulcer treatment, usage of antiulcerant drugs, and increase in prevalence of stomach cancer in the region are attributed to the growth of the market in North America. Furthermore, unhealthy lifestyles, high health care expenditure, and sophisticated health care infrastructure are the major factors fueling the growth of the market in the region. In addition, long R&D and approval cycles are required due to capital-intensive nature in North America, which act as a stumbling stone for the growth of the market in the region.
The antiulcerant drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, Takeda Pharmaceutical Company, Valeant, Zydus, Shire, Meritage Pharma, Medfit Biologicals., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiulcerant drugs market globally.
Overview: Allergan plc, incorporated in 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products.
Product Portfolio: The Company's portfolio comprised of pharmaceutical products of specialties for ophthalmologic care, neuromuscular, dermatological and urologic medical devices primarily facial aesthetics products, breast plastic products.
The global antiulcerant drugs market report would provide an access to an approx. 61 market data table, 61 figures and 200 pages.
LIST NOT EXHAUSTIVE